Not Signed In -
Glyburide |
Diabeta; Glynase; Micronase |
Clinical Trial: Determine whether glycemic control is different between Lantus & a 3rd oral agent when failure with other treatment
This study is currently recruiting patients.
|
Purpose
The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Diabetes Mellitus | Drug: Lantus (insulin glargine [rDNA origin] injection) Drug: Metformin Drug: Glyburide Drug: Thiazolidinedione | Phase IV |
MedlinePlus related topics: Diabetes
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Substituting Lantus®(insulin glargine[rDNAorigin]inj) for a thiazolidinedione vs. a 3rd oral agent as add-on therapy in patients failing a thiazolidinedione & sulfonylurea or Metformin Combination
Expected Total Enrollment: 240
Study start: November 2001
Eligibility
Ages Eligible for Study: 18 Years - 79 Years, Genders Eligible for Study: Both
Criteria
Key Inclusion:
- Patients between 18 - 79 years of age with diagnosed type 2 diabetes for at least a year treated with stable doses of two oral antidiabetic drugs of which one is either Avandia or Actos for at least three months.
Key Exclusion:
- Major cardiovascular events
Location and Contact Information
New Jersey
Aventis, Bridgewater, New Jersey, 08807, United States; Recruiting
More Information
Record last reviewed: April 2003
Last Updated: October 13, 2004
Record first received: September 30, 2002
ClinicalTrials.gov Identifier: NCT00046462
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
